Showing results (21-30 of 5,314) with videos related to
Sort By:
Pageof 532
BMC Medicine|November 9, 2022
Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatmentTimothée Olivier, Vinay PrasadMonash Bioethics Review|March 8, 2024
COVID-19 vaccines: history of the pandemic's great scientific success and flawed policy implementationVinay Prasad, Alyson HaslamTranslational Oncology|April 15, 2024
Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trialTimothée Olivier, Vinay PrasadContemporary Clinical Trials|December 25, 2013
The misguided ethics of crossover trialsVinay Prasad, Christine GradyJAMA Internal Medicine|September 12, 2017
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalVinay Prasad, Sham MailankodyTranslational Oncology|April 17, 2025
LUNAR: Full Moon or Eclipse? An exploration into tumor treating fields in lung cancerTimothée Olivier, Vinay PrasadThe Yale Journal of Biology and Medicine|December 20, 2011
Medical reversal: why we must raise the bar before adopting new technologiesVinay Prasad, Adam CifuTranslational Oncology|October 23, 2021
Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental armTimothee Olivier, Vinay PrasadCardiovascular Drugs and Therapy|October 3, 2018
Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?Rosa Ahn, Vinay PrasadTranslational Oncology|April 1, 2022
Tebentafusp in first-line melanoma trials: An outperforming outlierTimothée Olivier, Vinay PrasadPageof 532